Mark R. Chance, PhD
Director, Proteomics Core Facilitymark.email@example.com 216.368.4406 (o) 216.368.3812 (f)
Vice Dean for Research, Case Western Reserve University School of Medicine
Charles W. and Iona A. Mathias Professor of Cancer Research
Professor, General Medical Sciences
Member, GI Cancer Genetics Program
Mark R. Chance, PhD has worked at Case Western Reserve University since 2005, when he became director of the Center for Proteomics and Bioinformatics. From 2005 to 2010, he was a professor of physiology & biophysics in the School of Medicine at CWRU. In 2010, he became a professor in the Department of Genetics and Genome Sciences -- a position he still holds today – and from 2010 to 2014 he was a professor in the Department of General Medical Sciences. From 2010 to 2012, Dr. Chance was the interim chair for the Department of Genetics and Genome Sciences. In 2011, Dr. Chance became a Charles W. and Iona A. Mathias Professor of Cancer Research and Vice Dean for Research, both in the School of Medicine. In 2015, he became a professor in the Department of Nutrition. Since 2009, Dr. Chance has been the Chief Scientific Officer of NeoProteomics, Inc. in Cleveland, OH.
Dr. Chance earned his B.A. in biology from Wesleyan University in 1980. In 1984, he earned an OTH in biochemistry from MIT. He received his PhD in biophysics from the University of Pennsylvania in 1986. He also has relevant training in biophysics after working at AT&T Bell Labs. He is currently an Editorial Board Member for Cancer Genomics and Proteomics, the Journal of Clinical Biosciences, and Molecular and Cellular Proteomics.
Dr. Chance’s laboratory focuses its research on structural and cellular proteomics, specifically how revolutionary structural biology through structural genomics initiatives can be used to identify structures and functions of large macromolecular complexes in areas relevant to iron transport, mismatch repair, and actin filament assembly.
The proteomics core works with other investigators, including those at CWRU and those across northeast Ohio, to develop new biomarkers to help direct therapeutic approaches to patients. The lab is also comparing those new biomarkers to the fundamental regulatory mechanisms of diseases and biomarkers from normal development and physiology.
structural proteomics, cellular proteomics, structural biology, structural genomics, structural genomic initiatives, macromolecular complexes, iron transport, mismatch repair, actin filament assembly, biomarkers